Is MDG1.DE stock a buy after the pre-market drop?

MDG1.DE stock may be a tactical buy for short-term traders seeking an oversold bounce, but the company shows negative EPS **-1.21** and high volatility. Consider small position sizes and tight stops until fundamentals or clinical news improve.

What drives MDG1.DE stock volatility?

Volatility in MDG1.DE stock stems from low market cap, thin free float, clinical-readout risk, and episodic news flow; the recent volume spike to **189,470** shares amplified price moves and created the current oversold condition.

What price targets exist for MDG1.DE stock?

Meyka AI models a short-term bounce to **€0.25** and a conditional 12-month target of **€0.90**, both model-based projections and not guarantees; current price reference is EUR 0.1335 for comparison.

How does sector performance affect MDG1.DE stock outlook?

Healthcare sector averages offer context: Medigene’s current ratio **2.53** is similar to peers, but sector-wide clinical risk and capital intensity mean MDG1.DE stock needs positive trial or partnership news for sustained recovery.

DE Stocks

MDG1.DE Medigene AG XETRA -27.64% premarket 13 Mar 2026: Oversold bounce alert

ByDanny Kontos March 13, 2026

MDG1.DE stock plunged -27.64% in pre-market trade on 13 Mar 2026, leaving the share at €0.13 and creating an oversold bounce setup. Volume spiked to 189,470 shares, nearly 4.39x average, signalling capitulation near the session low of €0.08. We view this as a high-risk short-term bounce candidate, driven by a stretched technical move rather than fresh positive fundamentals. Traders should weigh sharply negative trailing metrics — EPS -1.21 and PE -0.11 — against a strong current ratio of 2.53 before sizing positions.